The earnings call highlighted strong progress in clinical trials and effective cost management, while also acknowledging the challenges of cash burn and reliance on trial outcomes.

Company Guidance

During Fulcrum Therapeutics' First Quarter 2025 Financial Results and Business Update Conference Call, several key metrics and guidance for the ongoing and future programs were discussed. The company highlighted the progress of their lead program, pociredir, which is currently in a Phase 1b trial for sickle cell disease. They successfully completed enrollment in the 12 mg cohort with 16 patients and plan to share results in early Q3, focusing on baseline patient characteristics, adverse events, and hematological parameters. The trial has shown greater than 90% adherence to the once-a-day regimen. The Data Monitoring Committee has recommended proceeding with the 20 mg cohort, expected to report data by the end of 2025. Financially, the company reported a significant reduction in research and development expenses to $13.4 million and a decreased net loss of $17.7 million for Q1 2025. Fulcrum ended the quarter with $226.6 million in cash and equivalents, projecting sufficient funding into 2027.

Successful Enrollment in PIONEER Phase 1b Trial

Fulcrum completed enrollment in the 12 mg cohort (Cohort 3) of the PIONEER trial for sickle cell disease with 16 patients enrolled. Data from this cohort will be shared in early Q3 2025.

Initiation of 20 mg Cohort in PIONEER Trial

Following a favorable review by the Data Monitoring Committee, the 20 mg cohort (Cohort 4) in the PIONEER trial has begun screening patients, with data expected by the end of 2025.

Financial Position and Cost Management

Net loss reduced to $17.7 million in Q1 2025 from $26.9 million in Q1 2024. R&D expenses decreased by $6.4 million year-over-year, and G&A expenses decreased by $3.1 million. Cash reserves are sufficient to fund operations into at least 2027.

European Hematology Association Meeting Participation

Two abstracts on pociredir have been accepted for presentation at the upcoming European Hematology Association meeting in June 2025.

Fulcrum Therapeutics (FULC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FULC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.29 / -	-0.35	―	―	―
Jul 29, 2025	2025 (Q2)	-0.29 / -0.28	0.87	-132.18% (-1.15)	―	―
May 01, 2025	2025 (Q1)	-0.29 / -0.28	-0.43	34.88% (+0.15)	―
Feb 25, 2025	2024 (Q4)	-0.28 / -0.31	-0.4	22.50% (+0.09)	―
Nov 13, 2024	2024 (Q3)	-0.40 / -0.35	-0.39	10.26% (+0.04)	―
Jul 31, 2024	2024 (Q2)	-0.41 / 0.87	-0.38	328.95% (+1.25)	―
May 13, 2024	2024 (Q1)	-0.44 / -0.43	-0.41	-4.88% (-0.02)	―
Feb 27, 2024	2023 (Q4)	-0.43 / -0.40	-0.5	20.00% (+0.10)	―
Nov 07, 2023	2023 (Q3)	-0.44 / -0.39	-0.51	23.53% (+0.12)	―
Aug 03, 2023	2023 (Q2)	-0.45 / -0.38	-0.83	54.22% (+0.45)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FULC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$7.81	$7.59	-2.82%
May 01, 2025	$3.85	$4.38	+13.77%
Feb 25, 2025	$3.70	$3.70	0.00%
Nov 13, 2024	$3.64	$3.56	-2.20%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fulcrum Therapeutics (FULC) report earnings?

Fulcrum Therapeutics (FULC) is schdueled to report earning on Nov 12, 2025, Before Open (Confirmed).

What is Fulcrum Therapeutics (FULC) earnings time?

Fulcrum Therapeutics (FULC) earnings time is at Nov 12, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FULC EPS forecast?

FULC EPS forecast for the fiscal quarter 2025 (Q3) is -0.29.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing